SS Innovations Reports Second Quarter 2026 Financial Results

FORT LAUDERDALE, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- via IBN – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and six months ended June 30, 2026. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, with the Securities and Exchange Commission on August 13, 2026.

Second Quarter 2026 Overview * Revenue increased 39.4% to $13.9 million from $10.0 million in the second quarter of 2025. * Gross margin equaled 50.9%, compared to 59.1% in the second quarter of 2025. * Gross profit rose 20.0% to $7.1 million from $5.9 million in the second quarter of 2025. * Net loss of $2.7 million, or $(0.01) per diluted share, compared to a net loss of $0.3 million, or $(0.00) per diluted share, in the second quarter of 2025. * SSi Mantra surgical robotic system installations totaled 30, up 30.4% from 23 installations in the second quarter of 2025. First Half 2026 Overview * Revenue increased 65.6% to $25.0 million from $15.1 million in the first half of 2025. * Gross margin expanded to 49.6% from 46.3% in the first half of 2025. * Gross profit rose 77.5% to $12.4 million from $7.0 million in the first half of 2025. * Net loss of $6.2 million, or $(0.03) per diluted share, compared to a net loss of $5.9 million, or $(0.03) per diluted share, in the first half of 2025. * SSi Mantra surgical robotic system installations totaled 56, up 47.4% from 38 installations in the first half of 2025. As of June 30, 2026 * Long-term debt of $0. * Cash and cash equivalents totaled $13.6 million, excluding restricted cash. * SSi Mantra cumulative installed base totaled 224 systems across twelve countries and cumulative surgeries reached 12,272, including 175 telesurgeries, 637 cardiac procedures and 222 pediatric surgeries. CEO Commentary